ReviewPolymers2023
Microbial Exopolysaccharide Composites in Biomedicine and Healthcare: Trends and Advances.
Review in Polymers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- A systematic review of structure-activity relationships in bacterial levan: physicochemical mediation and context-dependent functionality.RSC advances · 2026Review
- Isolation and preliminary characterization of a glucan-type exopolysaccharide produced by Bacillus tequilensis strain HH from Egyptian fermented cucumber.Scientific reports · 2026Article
- Biofilm formation in Streptomyces nigra strain KDS4 and characterization of extracellular polymeric substances (EPS) for biomaterial development.World journal of microbiology & biotechnology · 2026Article
- Starch-Based Functional Ingredients in Baking: A Review of Advances in Starch Derivatives, Quality Enhancement, and Reduction of Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols.Molecules (Basel, Switzerland) · 2026Review
- Enhanced Barley Growth in Petroleum-Contaminated Soil Mediated by Xanthan-like Exopolysaccharide ofMicroorganisms · 2026Article
- Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Characterization of Mannose-Rich Exopolysaccharides from Kefir Lactic Acid Bacteria and Their Techno-Functional Potential in Fermented Milk.Foods (Basel, Switzerland) · 2026Article
- Article
- Production and characterization of exopolysaccharides from Pseudomonas aeruginosa AG01 with some medical potential applications.Microbial cell factories · 2025Article
- Burn Wound Healing Abilities of a Uronic Acid Containing Exopolysaccharide Produced by the Marine Bacterium Halomonas malpeensis YU-PRIM-29Applied biochemistry and biotechnology · 2024Article
- Optimizing Exopolysaccharide Production by Bacillus subtilis Using Spoiled Fig and Grape.Current microbiology · 2024Article
- Co-delivery of siRNA and cisplatin via electrospun Nanofibrous membranes for synergistic treatment of malignant melanoma.Heliyon · 2024Article
- Rhizosphere bacterial exopolysaccharides: composition, biosynthesis, and their potential applications.Archives of microbiology · 2024Review
- Structural and Physiochemical Properties of Polyvinyl Alcohol-Succinoglycan Biodegradable Films.Polymers · 2024Article
- Revisiting microbial exopolysaccharides: a biocompatible and sustainable polymeric material for multifaceted biomedical applications.3 Biotech · 2024Review
- Levan Production byMolecules (Basel, Switzerland) · 2024Article
- Article
- Exploring Extremophiles from Bulgaria: Biodiversity, Biopolymer Synthesis, Functional Properties, Applications.Polymers · 2023Review
- Production of Exopolysaccharide-Based Porous Structures for Biomedical Applications: A Review.Nanomaterials (Basel, Switzerland) · 2023Review
- Production of Bacterial Exopolysaccharides: Xanthan and Bacterial Cellulose.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial exopolysaccharides (EPSs), e.g., xanthan, dextran, gellan, curdlan, etc., have significant applications in several industries (pharma, food, textiles, petroleum, etc.) due to their biocompatibility, nontoxicity, and functional characteristics. However, biodegradability, poor cell adhesion, mineralization, and lower enzyme activity are some other factors that might hinder commercial applications in healthcare practices. Some EPSs lack biological activities that make them prone to degradation in ex vivo, as well as in vivo environments. The blending of EPSs with other natural and synthetic polymers can improve the structural, functional, and physiological characteristics, and make the composites suitable for a diverse range of applications. In comparison to EPS, composites have more mechanical strength, porosity, and stress-bearing capacity, along with a higher cell adhesion rate, and mineralization that is required for tissue engineering. Composites have a better possibility for biomedical and healthcare applications and are used for 2D and 3D scaffold fabrication, drug carrying and delivery, wound healing, tissue regeneration, and engineering. However, the commercialization of these products still needs in-depth research, considering commercial aspects such as stability within ex vivo and in vivo environments, the presence of biological fluids and enzymes, degradation profile, and interaction within living systems. The opportunities and potential applications are diverse, but more elaborative research is needed to address the challenges. In the current article, efforts have been made to summarize the recent advancements in applications of exopolysaccharide composites with natural and synthetic components, with special consideration of pharma and healthcare applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.